Capital Fund Management S.A. Purchases 113,780 Shares of TransMedics Group, Inc. (NASDAQ:TMDX)

Capital Fund Management S.A. increased its position in TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) by 940.3% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 125,880 shares of the company's stock after purchasing an additional 113,780 shares during the quarter. Capital Fund Management S.A. owned approximately 0.38% of TransMedics Group worth $7,849,000 as of its most recent SEC filing.

Several other hedge funds have also bought and sold shares of the company. National Bank of Canada FI boosted its stake in shares of TransMedics Group by 174.7% during the 3rd quarter. National Bank of Canada FI now owns 412 shares of the company's stock worth $65,000 after acquiring an additional 262 shares during the period. Atlas Capital Advisors Inc. acquired a new stake in TransMedics Group during the fourth quarter worth approximately $31,000. Hager Investment Management Services LLC bought a new stake in shares of TransMedics Group during the fourth quarter worth approximately $33,000. Sachetta LLC acquired a new position in shares of TransMedics Group in the fourth quarter valued at approximately $40,000. Finally, AlphaQuest LLC bought a new position in shares of TransMedics Group during the fourth quarter worth approximately $52,000. 99.67% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research analysts have commented on the company. Canaccord Genuity Group reaffirmed a "buy" rating and issued a $104.00 price objective on shares of TransMedics Group in a report on Tuesday, March 11th. JPMorgan Chase & Co. reissued a "neutral" rating and issued a $75.00 price objective (down previously from $116.00) on shares of TransMedics Group in a report on Tuesday, December 17th. Finally, Needham & Company LLC reiterated a "hold" rating on shares of TransMedics Group in a research report on Wednesday, March 26th. Three research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, TransMedics Group currently has a consensus rating of "Moderate Buy" and an average target price of $122.70.

Remove Ads

TransMedics Group Price Performance

NASDAQ TMDX traded up $0.34 during trading on Tuesday, hitting $87.18. 1,255,749 shares of the company's stock were exchanged, compared to its average volume of 1,337,395. The company has a market cap of $2.93 billion, a PE ratio of 92.75 and a beta of 2.14. The company has a current ratio of 8.20, a quick ratio of 7.33 and a debt-to-equity ratio of 2.42. TransMedics Group, Inc. has a fifty-two week low of $55.00 and a fifty-two week high of $177.37. The stock's 50 day moving average price is $71.46 and its two-hundred day moving average price is $80.72.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.